News

Individuals in the study were assessed two years after NX-1207 treatment for symptomatic improvement, treatment outcomes, and durability of efficacy. This is the largest cohort of patients treated

The existing boxed warning has been revised to add the FDA’s conclusion that, while an FDA meta-analysis of short-term studies, mostly against placebo, showed an association between Avandia

The company expects to announce results from the trial in late 2008. CERE-120 is designed to deliver the neurturin gene, a nervous system growth factor with the ability

Invitrogen’s patent applications which are part of this agreement cover stealth and other proprietary technologies related to enhanced configurations of chemically modified double-stranded RNA. Dr Tod Woolf, president

Excellarate is a DNA-based topical gel that is being developed to be administered once or twice to stimulate wound healing. The trial, known as MATRIX (GAM501 for the

Christopher Reinhard, chairman and CEO of Cardium and InnerCool, said: “Cardium and InnerCool recently announced the launch of the new CoolBlue surface-based patient temperature modulation system and expect

Including the over-allotment, the company sold 11.5 million shares in the offering, resulting in net proceeds of approximately $83.4 million after deducting the underwriting discounts and commission and

Cyberkinetics and NeuroMetrix have also agreed to negotiate a joint venture to develop and commercialize a therapeutic product for peripheral nerve injury based on Cyberkinetics’ Andara Oscillating Field

Patients undergoing laser treatment were 33% more likely to experience pain and 50% more likely to require postoperative pain medication than patients who received the ClosureFast treatment. The